GlobeNewswire Inc | Nov 9, 2021 06:30AM EST

November 09, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming 2021 virtual investor conferences:

Stifel 2021 Virtual Healthcare Conference Monday, November 15, 2021, 2:40pm ET

Jefferies London Healthcare Conference Thursday-Friday, November 18-19, 2021; presentation available on-demand beginning November 18, 2021, 3:00am ET

33rd Annual Piper Sandler Healthcare ConferenceTuesday-Thursday, November 30-December 2, 2021; presentation available on-demand beginning November 22, 2021, 10:00am ET

Evercore ISI Healthcare ConferenceWednesday, December 1, 2021, 1:25pm ET

Live webcasts of presentations will be available under the Investors and Media section of NGMs website at https://ir.ngmbio.com/events-presentations. A replay of each presentation will be archived on NGMs site for at least 30 days following the event.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying retinal diseases, cancer and liver and metabolic diseases. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. All of our therapeutics have been generated by our in-house discovery engine; today, we have seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutics areas. Visit us at www.ngmbio.com for more information.

Investor Contact: Media Contact:Brian Schoelkopf Liz Meloneir@ngmbio.com media@ngmbio.com